Metabolism and phospholipid assembly of polyunsaturated fatty acids in human bone marrow mesenchymal stromal cells by Tigistu-Sahle, Feven et al.
92 Journal of Lipid Research Volume 58, 2017
Copyright © 2017 by the American Society for Biochemistry and Molecular Biology, Inc.
This article is available online at http://www.jlr.org
Mesenchymal stromal/stem cells (MSCs) are cells with 
multi-lineage differentiation (1) and immunomodulatory 
capacity (2–4). These characteristics of MSCs, especially 
their ability to inhibit the proliferation of antigen-specific 
memory T cells (5, 6), have made them excellent candi-
dates for various cell-based therapies (7), including the 
treatment or prevention of graft versus host disease (8), 
autoimmune diseases (9), and solid organ transplantation 
rejections (10). In order to successfully apply these cells for 
therapeutic applications, substantial in vitro expansion is 
required. However, long-term culturing of MSCs contrib-
utes to their loss of stem cell characteristics manifested in 
decreased proliferation and differentiation potential, telo-
mere shortening, and accumulation of n-6 PUFAs with sig-
naling roles promoting inflammatory conditions (11–13). 
Thus, developing a safe method to preserve stem cell pro-
liferation, differentiation, and immunomodulatory poten-
tial is of paramount importance.
PUFAs and their bioactive derivatives affect the prolif-
eration and differentiation of various stem cells and mod-
ulate their immunological interactions with other cells 
(14–20). In most mammalian cell types, exogenous lin-
oleic acid (18:2n-6) or -linolenic acid (18:3n-3) is desatu-
rated and elongated to arachidonic acid (20:4n-6) or to 
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22:6n-3 between the different GPL classes in the cells sup-
plemented with either the first n-6 or n-3 family precursors 
or their elongated and highly unsaturated products. This 
work reveals the urgent need to revise the culture proce-
dures used when expanding therapeutic MSCs and lays the 
foundations for future trials of manipulating MSC func-
tionality by the means of different PUFA supplements.
MATERIALS AND METHODS
Ethics and bone marrow donors
Human bone marrow aspirates (n = 4) and hBMSC lines (n = 
4) were included in the current study. The Ethical Committee of 
Northern Ostrobothnia Hospital District approved all the patient 
protocols, and the use of human material conforms to the prin-
ciples outlined in the Declaration of Helsinki. Informed written 
consent was acquired from adult patients prior to collecting bone 
marrow aspirates from the iliac crest.
Materials
The hBMSCs were obtained from the clinic of Professor Petri 
Lehenkari and HepG2 (liver hepatocellular carcinoma) cells 




Type Culture Collection (Rockville, MD) and fatty acid-free BSA 
from Sigma (St. Louis, MO). FFAs 18:2n-6, 18:3n-3, 20:4n-6, 
20:5n-3, and 22:6n-3 were obtained from Nu-Chek-Prep, Inc. 
(Elysian, MN).
Cell culture of hBMSCs and HepG2 cells
The hBMSCs that had been harvested between passages 3 and 
5 were cultured in -MEM medium and supplemented with 5% 
FBS, 2 mM L-glutamine, 100 u/ml penicillin, 100 g/ml strepto-
mycin, and 20 mM HEPES. HepG2 cells between passages 84 and 
86  were  cultured  in  E-MEM  and  supplemented  with  10%  non-
heat inactivated FBS, 2 mM L-glutamine, 100 u/ml penicillin, and 
100 g/ml streptomycin. Both cell types were plated on 75 cm2 
flasks at a density of 2.5 × 103 cells/cm2.
In order to compare the metabolism and incorporation pat-
tern of different PUFAs into membrane GPLs, the cells were sup-
plemented with specific PUFAs: 18:2n-6, 18:3n-3, 20:4n-6, 20:5n-3, 
or 22:6n-3 bound to BSA at 50 M concentration (FFA/BSA 
2.7:1). Ethanol was used to prepare the stock solutions of FFAs 
at a concentration of 100 mM. The cells were incubated in a 
humidified incubator at 37°C and 5% CO2, and cultured for 
nine consecutive days (until 70–80% confluence). The medium 
was renewed every 72 h and each time replenished with the 
same FFAs.
GC of fatty acids
Transmethylation of hBMSC and HepG2 lipids was per-
formed according to the recommendations of Christie (33). 
Samples were heated in 1% H2SO4 in methanol, at a tempera-
ture of 96°C and under nitrogen atmosphere for 120 min. The 
fatty acid methyl esters formed were recovered with hexane 
and analyzed using a gas chromatograph (Shimadzu GC-2010 
Plus) equipped with an auto injector (AOC-20i), flame ionization 
detector, and ZB-wax capillary columns (30 m, 0.25 mm ID, 
0.25 m film; Phenomenex USA). The identification of the fatty 
acid methyl esters was based on the retention time, the use of 
eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid 
(22:6n-3), respectively. These resulting PUFAs are at first 
incorporated into membrane glycerophospholipids (GPLs), 
and then deliberated by phospholipases to be employed as 
precursors to produce various lipid mediators. Three ma-
jor synthetic pathways, namely, cyclooxygenase (COX), li-
poxygenase (LOX), and cytochrome P450, produce lipid 
mediators such as prostaglandins, leukotrienes, thrombox-
anes, lipoxins, and resolvins, collectively termed eicosanoids 
and  docosanoids.  Prostaglandin  E2  (PGE2;  derivative  of 
20:4n-6) is known to affect the proliferation and cytokine 
secretion of T cells, and thus has a major role in MSC im-
munoregulation (21). Recently, lipoxins and resolvins have 
been identified as essential regulators of the resolution 
phase of inflammation (22) and as players in the immuno-
regulation of MSCs (23).
For MSC therapy, the human bone marrow-derived 
MSCs are the best-characterized and most widely used cells. 
MSCs have also been isolated from various adult and fetal 
tissues, including synovium, periosteum, skeletal muscle, 
cord blood, and adipose tissue (24–27). The fatty acid com-
position of bone marrow, harboring MSCs, is prone to 
changes due to diet, age, or clinical status of the patient 
(28, 29). Therefore, the variable marrow microenviron-
ment that surrounds and nourishes human bone marrow 
mesenchymal stromal cells (hBMSCs) can also affect the 
functional properties of the cells (13). In addition, it is logi-
cal to assume that hBMSCs, which are commonly cultured 
with PUFA supplements very different from the PUFAs 
found in the human bone marrow, have altered functional 
properties. In order to evaluate how well the PUFA supply 
of hBMSCs in vitro resembles that in vivo, we first com-
pared the fatty acid composition in human bone marrow 
aspirations to the fatty acid supplement of the culture me-
dia, i.e., the FBS.
The endogenous capacity of cultured hBMSCs to modify 
PUFA structures for their functional needs could partially 
compensate for suboptimal supply from the microenviron-
ment, culture media, or the marrow in vivo. Still today, 
information on mammalian PUFA metabolism largely orig-
inates from studies on cultured hepatocytes, which have 
excellent capacity to metabolize diet-derived PUFAs (30, 
31). However, some eukaryotic cell types, such as platelets 
and macrophages, lymphoblasts, and metastatic mammary 
cells, are deficient in performing desaturation steps for 
PUFA precursors (32). Because the PUFA metabolism of 
hBMSCs has not been studied before, in this work we char-
acterized the capacity of cultured hBMSCs to modify exog-
enously administered 18-carbon (C18) PUFA precursors 
into their elongated and highly unsaturated products. The 
practical goal was to find out which fatty acid supple-
ments could specifically modify the contents of the most 
bioactive PUFAs, i.e., 20:4-6, 20:5n-3, and 22:6n-3, of the 
cells and, thereby, affect their immunomodulatory proper-
ties. Because the phospholipases deliberating PUFAs for 
signaling act on specific GPLs, detailed analysis of the in-
corporation patterns of different PUFAs into different GPL 
classes was also carried out. It was especially important 
to compare the distribution of the 20:4n-6, 20:5n-3, and 
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centrifuged at 2,000 g for 10 min, and the supernatant was further 
ultracentrifuged at100,000 g for 2 h at 4°C. This latter superna-
tant, free of extracellular vesicles, was collected and PGE2 levels 
were  measured  by  using  a  PGE2  ELISA  kit  [monoclonal  item 
number 514010 (Cayman Chemical, Ann Arbor, MI)] according 
to the manufacturer’s protocol. For the absorbance (405 nm) 




showed that potential cross-reactivity from other prostaglandins 
did not bias the data.
Statistical analysis
To study statistical differences between the fatty acid and lipid 
levels in different experimental samples, the Kruskal-Wallis 
nonparametric one-way ANOVA followed by a post hoc Mann-
Whitney test for the means was used. The data represent four 
replicates of hBMSCs for each PUFA supplementation trial, four 
clinical bone marrow aspirates, and five FBS samples from differ-
ent lots. P < 0.05 was regarded as statistically significant.
Gene expression analysis
RNA was extracted using Qiagen AllPrep DNA/RNA mini kit 
(Qiagen, Valencia, CA) and a Qiagen supplementary protocol 
(Purification of total RNA containing miRNA from animal cells 
using the RNAeasy Plus mini kit). A detailed description on the 
hybridization of labeled RNAs (onto Agilent SurePrint G3 Hu-
man GE 8 × 60 K), scanning of the slides, and processing, trans-
forming, and modeling of the data are found in Kilpinen et al. 




fatty acid elongases and desaturases found in MSCs and hepato-
cytes were retrieved from the updated version of public database, 
GeneSapiens, which is currently hosted by MediSapiens Ltd. un-
der the name IST online (41).
RESULTS
Cultured hBMSCs are commonly supplemented with 
FBS, the PUFA composition of which differs from that of 
human bone marrow
The fatty acid profiles of the hBMSCs cultured in stan-
dard medium were compared with those in the FBS and 
human bone marrow samples (Fig. 1). The total levels of 
saturated fatty acids (SFAs) in the hBMSCs were 42%, be-
tween the levels of FBS and the marrow (Fig. 1A). Among 
individual SFAs, the hBMSCs contained less 16:0, but more 
18:0, than the FBS and marrow samples (Fig. 1B). The ma-
jor MUFA, 18:1n-9, was found in hBMSCs and FBS with 
levels one-half of those in the marrow. Compared with 
hBMSC levels, both the bone marrow and the FBS were 
rich sources of 18:2n-6 (Fig. 1C). A striking finding was that 
hBMSCs, like their common FBS supplement, contained 
large reservoirs of 20:4n-6 (hBMSC 12%, FBS 9%), about 
10 times the levels found in the bone marrow (Fig. 1C). 
Compared with FBS levels, the hBMSCs had a 1.4-fold in-
crease in their relative amount of 20:4n-6. Interestingly 
this increase for 22:4n-6 was even 3.7-fold. The n-3 PUFA 
authentic standard mixtures of known composition, and confir-
matory recordings of mass spectra (Agilent 6890N network GC 
with FID and 5973 MSD). Quantifications were based on FID 
responses corrected according to the theoretical response fac-
tors (34) and calibrations with the quantitative authentic stan-
dards. The fatty acid proportions were calculated as mole percent 
(later percent), and the fatty acids were marked by using the 
abbreviations:  [carbon  number]:[number  of  double  bonds]n-
[position  of  the  first  double  bond  calculated  from  the  methyl 
end] (e.g., 22:6n-3).
MS of GPLs
For MS, total lipids were extracted from hBMSCs and HepG2 
cells according to Folch, Lees, and Sloane Stanley (35). Samples 
dissolved in chloroform/methanol (1:2 v/v) were spiked with in-
ternal standards and supplemented with 1% NH4OH just before 
direct infusion of the sample solution into the ESI source of a tri-
ple quadrupole mass spectrometer (Agilent 6490 Triple Quad 
LC/MS with iFunnel technology; Agilent Technologies, Inc., 
Santa Clara, CA) at a flow rate of 10 l/min. The instrument’s 
response for different GPLs is affected by the head groups and 
acyl chain structures. Thus, a cocktail of 13 internal standards was 
added to each sample solution to correct for such variations and 
improve the precision of quantitative analysis. In addition to the 
MS+ and MS scans, MS/MS precursor ion scans were used to 
detect phosphatidylcholine (PC) species (precursors for the frag-
ment ion m/z 184) and phosphatidylinositol (PI) species (precur-
sors for m/z 241). MS/MS neutral loss scans were applied to detect 
phosphatidylethanolamine  (PE)  (neutral  loss  of  141  amu)  and 
phosphatidylserine (PS) species (neutral loss of 87 amu). PE plas-
malogen (PEp) species were detected according to the fragments 
specific for the vinyl ether chain at the sn-1 position [e.g., m/z 364, 
390, and 392 for 16:0p, 18:1p, and 18:0p, respectively (36)]. Tria-
cylglycerol (TAG) species were detected as (M+NH4)
+ ions (37) 
and their concentrations were normalized against total PC con-
centration calculated from the same MS+ scan. For the MS analy-
ses, a source temperature of 250°C and instrument collision 
energies of 5–45 eV (optimal settings depend on the lipid class) 
were used. Nitrogen was used as the nebulizing (20 psi) and the 
drying gas (11 l/min at 250°C). The spectra generated by the 
instrument were processed by MassHunter Workstation qualita-
tive analysis software (Agilent Technologies, Inc.) and the indi-
vidual GPL species were quantified using the internal standards 
and free software called Lipid Mass Spectrum Analysis (LIMSA) 
(38). Using this software, the spectral peak intensities were con-
verted to concentrations expressed as mole percent (later per-
cent) for each lipid species (relative to the total amount in the 
lipid class). The acyl chain assemblies in each lipid species were 
studied by recording negative ion mode product ion scans of the 
anion fragments for all common fatty acids (39). For PC species, 
which do not ionize in negative mode as such, formate adducts 
served as mother ions, and yielded the anionic fragments of the 
acyl chains. Provided that the GC analyses had shown that only 
one quantitatively important double bond positional isomer was 
present for a certain fatty acid of the cells, these acyl chains in 
GPL were marked using the known accurate structure.
PGE2 production in hBMSCs
To measure PGE2 production, hBMSCs were grown in the con-
trol medium (-MEM with 5% FBS) or  in  the medium  supple-
mented with different PUFAs conjugated to BSA, as described 
above. After 24 h incubation, the medium was aspirated, and 
the cells were washed twice with PBS and once with serum-free 
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hBMSCs elongate C18 PUFA precursors, but fail to 
produce highly unsaturated fatty acids
Supplementing the hBMSCs with the C18 PUFA precur-
sors, 18:2n-6 or 18:3n-3, decreased the SFA and MUFA con-
tents of the cells (Fig. 2A). The contents of the main 
individual MUFAs, 18:1n-9 and 18:1n-7, of the fatty acid-
supplemented hBMSCs were halved from the levels of the 
cells cultured in standard medium (Fig. 2B). Incubating 
the hBMSCs with 18:2n-6 caused a 10-fold increase in its 
relative amount compared with the cells grown in standard 
medium, from 3% to 37% (Fig. 2C). At the same time, the 
level of the immediate elongation product of 18:2n-6, i.e., 
precursor,  18:3n-3,  was  present  with  1%  in  the  marrow, 
clearly exceeding the contents in the hBMSCs and FBS, but 
the long-chain and highly unsaturated members of the n-3 
family, 20:5n-3, 22:5n-3, and 22:6n-3, were more abundant 
in the hBMSCs and their FBS supplement than in the mar-
row (Fig. 1D). When the levels of 20:5n-3 and 22:6n-3 
equaled in the hBMSCs and FBS, the 22:5n-3 was enriched 
in the cells 1.8-fold. These findings raised the question of 
whether all n-3 and n-6 PUFAs provided by the culture me-
dium or natural niche are biologically equally active and 
metabolized further in the hBMSCs to form even longer 
and more highly unsaturated fatty acids.
Fig. 1. Fatty acid profiles (mole percent in total fatty 
acids, mean ± SD) in hBMSCs (SC, in control medium, 
n = 4) compared with those in different lots of FBS 
(n = 5) and in clinical samples of human bone marrow 
(BM, n = 4). A: Total proportions of SFAs, MUFAs, 
PUFAs, n-6 PUFAs, and n-3 PUFAs The ratio of n-3 to 
n-6 PUFAs (n-3/n-6) is shown in the insert. B: Individ-
ual SFAs and MUFAs. The ratio of MUFA total to SFA 
total is shown in the insert. C: Individual n-6 PUFAs. D: 
Individual n-3 PUFAs. As statistics, Kruskal-Wallis non-
parametric one-way ANOVA followed by post hoc 
Mann-Whitney test for the means were used. The 
means with no common letter differed at the P < 0.05 
level. Missing letters on the bars mean that the Kruskal-
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of 18:3n-3, i.e., 20:3n-3, showed a 25-fold increase. In addi-
tion, 20:4n-3 and 20:5n-3, which follow on the metabolic 
pathway, had raised their levels as a consequence of the 
exogenous 18:3n-3 supply. However, this trend was re-
versed for the longest and most highly unsaturated n-3 
PUFAs, 22:5n-3 and 22:6n-3, which declined by 40% due to 
the supplementation. In addition, the 18:3n-3 supplement 
decreased the levels of 20:4n-6 and 22:4n-6 (Fig. 2C).
20:2n-6, was increased 30-fold. In contrast, 20:4n-6 de-
creased by more than 60% from the level of the standard 
cells. Raising the 18:2n-6 concentration in the growth me-
dium also reduced the levels of 22:5n-3 and 22:6n-3 in the 
hBMSCs (Fig. 2D). Similarly to the effects seen after add-
ing 18:2n-6 to the cells, the 18:3n-3 supplementation also 
raised its own relative amount in the cells, from a negligible 
level to 21% (Fig. 2D). The immediate elongation product 
Fig. 2. Comparison of the fatty acid profiles (mole 
percent in total fatty acids, mean ± SD) in control 
(Ctrl) and 18:2n-6- or 18:3n-3-supplemented hBMSCs 
(SC) and HepG2 (Hep) cells (n = 4). A: Total propor-
tions of SFAs, MUFAs, PUFAs, n-6 PUFAs, and n-3 
PUFAs. B: Individual SFAs and MUFAs. C: Individual 
n-6 PUFAs. D: Individual n-3 PUFAs. Statistics are as in 
Fig. 1. In the cases where a value exceeded the scale, 
the value was shown at the top of the bar.
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Fig. 3. Scheme of the metabolism of n-6 and n-3 
PUFAs in the hBMSCs and HepG2 cells by desaturase 
and elongase enzymes. The average levels of different 
PUFAs in hBMSCs and HepG2 cells on the pathways 
are visualized with bars and related values (mole per-
cent) of the cells grown in control (Ctrl) media. The 
measured mRNA levels of the elongases (ELOVL5 and 
ELOVL2) and desaturases (FADS2, FADS1)  involved 
are marked inside the blue ovals. The values inside the 
arrows are the average expression levels of the en-
zymes that were obtained for mesenchymal stem cells 
(SC) from a public online database, IST, and normal-
ized against hepatocyte (Hep) values of the database. 
Per -ox, peroxisomal partial -oxidation.
Different metabolism of C18 PUFA precursors in 
hBMSCs and HepG2 cells
Unlike hBMSCs, the comparison HepG2 cells effectively 
modified exogenous 18:2n-6 and 18:3n-3 and produced 
longer and more unsaturated PUFAs, especially 20:4n-6 
(Fig. 2C), 20:5n-3, and 22:5n-3 (Fig. 2D). Consequently, 
the HepG2 cells accumulated clearly less 18:2n-6 and 
18:3n-3, only one-third of the relative amount that the cor-
responding hBMSCs accumulated. The apparent disparity 
in PUFA metabolism between the hBMSCs and HepG2 
cells pointed to differences in the expression levels of the 
enzymes responsible for the acyl chain elongation or de-
saturation steps. Thus the mRNA levels in the hBMSCs 
(passage 4 cells grown in standard medium) were studied 
for the fatty acid elongases, ELOVL2 and ELOVL5, and for 
the fatty acid desaturases, FADS1 (5 desaturase) and 





els for enzymes modifying fatty acid structures were also 
retrieved from the public online database, IST, and the val-
ues for MSCs and HepG2 cells were compared (Fig. 3). 
The MSC expression levels of ELOVL5 and ELOVL2 were 
0.8 and 1.9 times the values of the HepG2 cells, suggesting 
no significant defects. The mRNA values of the hBMSCs 
for FADS1 and FADS2 were in the same range (11.5 and 
9.1, respectively). However, the MSC expression levels for 
FADS1 (5) were low, only 0.6 times those found in the 
HepG2 cells. MSC FADS2 (6) expression level was 1.2 
times that of HepG2 cells. In the database, the SCD (9 
desaturase, converting SFAs to MUFAs) expression level of 
MSCs was reported to be even 2.7 times higher than the 
levels of HepG2 cells, thus low MUFA contents of hBMSCs 
compared with HepG2 cells were not due to insufficient 
SCD expression.
C20 or C22 highly unsaturated fatty acid supplements 
efficiently and specifically modify the contents of these 
fatty acids in hBMSCs
In addition to supplementing the cell cultures with 
C18 precursors, parallel experiments were carried out 
that focused on the effects of longer and highly unsatu-
rated members of the n-6 and n-3 PUFAs on the fatty acid 
profiles of the hBMSCs. The levels of SFAs and especially 
those of MUFAs, were decreased by the C20 and C22 
PUFA supplements, but in general these effects were not 
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Among n-3 PUFAs, the immediate elongation product of 
20:5n-3, i.e., 22:5n-3, was raised almost 4-fold due to the 
20:5n-3 supplement (Fig. 4C). However, the level of 22:6n-3 
(the synthesis of which requires two chain elongations, one 
desaturation, and one peroxisomal chain shortening step 
for the precursor 22:5n-3) did not increase, but decreased 
by 62% in hBMSCs.
Culturing hBMSCs in 22:6n-3-supplemented medium re-
sulted in 6-fold increase in the relative amount of 22:6n-3 
compared with the cells kept in standard medium (Fig. 4C). 
The preceding n-3 family member, 22:5n-3, got 35% lower 
levels compared with the cells cultured in standard medium. 
as strong as seen in C18 PUFA supplementation experi-
ments (Fig. 4A). 
As a result of 20:4n-6 supplementation, the hBMSC lev-
els of 20:4n-6 doubled, from 12% to 23% (Fig. 4B). In ad-
dition, the supplement caused a 6-fold increase in the level 
of 22:4n-6, from 2% to 13%. Culturing the cells in 20:5n-
3-supplemented medium resulted in a 20-fold increase in 
the relative amount of 20:5n-3, compared with the cells 
grown  in  standard medium,  from 1%  to 13%,  (Fig. 4C). 
The added 20:5n-3 had a lowering effect on n-6 PUFA con-
tent, especially on the 20:4n-6 levels, which decreased by 
60%,  and  a  clear  reduction  was  also  found  for  22:4n-6. 
Fig. 4. Fatty acid profiles (mole percent in total fatty 
acids, mean ± SD) in hBMSCs (n = 4) cultured for 9 
days in the control (Ctrl) medium or media supple-
mented with different n-6 and n-3 PUFAs. A: Profiles 
of individual SFAs and MUFAs in cells cultured in the 
Ctrl medium and in the cells the medium of which was 
supplemented with 18:2n-6, 20:4n-6, 18:3n-3, 20:5n-3, 
or 22:6n-3. B: Profiles of PUFAs in the cells cultured in 
the Ctrl medium and in the medium supplemented 
with 18:2n-6 or 20:4n-6. C: PUFA profiles in the cells 
cultured in the Ctrl medium and in the medium sup-
plemented with 18:3n-3, 20:5n-3, or 22:6n-3. Statistics 
are as in Fig. 1. In the cases where the value exceeded 
the scale, the mean and SD are shown at the top of the 
bar. D: Scheme of the metabolism of n-6 and n-3 
PUFAs in the hBMSCs cultured in control (Ctrl) me-
dium or media supplemented with the different n-6 
and n-3 PUFAs. The enzymes metabolizing the PUFAs 
are indicated (abbreviations explained in Fig. 3). The 
values on the bars represent mole percent of the PUFAs 
per total fatty acids.
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Fig. 4. continued.
The addition of 22:6n-3 lowered the hBMSC levels of 
20:4n-6 and 22:4n-6 by 45% (Fig. 4C), resembling the ef-
fect of the 20:5n-3 supplement. When examining the dif-
ferences in the metabolic PUFA pathways of hBMSCs due 
to the different PUFA supplements, it became evident that 
on the n-6 PUFA pathway only 20:4n-6 efficiently raised the 
total 20:4n-6 and 22:4n-6 contents of the cells (Fig. 4D). On 
the n-3 PUFA pathway, only 20:5n-3 raised the cellular lev-
els of 20:5n-3 and 22:5n-3. The hBMSC level of 22:6n-3 was 
increased only by the 22:6n-3 supplement.
Pronounced TAG accumulation in hBMSCs supplemented 
with n-6 PUFAs
Prominent, but variable, accumulation of unsaturated 
TAG was detected in the hBMSCs supplemented with 
18:2n-6 (supplemental Fig. S1). In addition, the TAG levels 
of the 20:4n-6-supplemented cells were statistically signifi-
cantly higher than those of the n-3 PUFA-supplemented 
cells. The control cells had the lowest TAG levels.
GPL molecular species profiles of hBMSCs differ after 
18:2n-6 and 20:4n-6 supplementations
The incorporation of different PUFAs into GPL molecu-
lar species was studied in the hBMSCs that were cultured 
in standard growth medium or in media supplemented 
with either 18:2n-6 or 20:4n-6 (Figs. 5–7). Supplementing 
the media with the different n-6 PUFAs modified the 
PC molecular species profiles of the hBMSCs largely 
(Fig. 5). The relative amounts of monounsaturated PC 
species (32:1, 34:1, and 36:1) decreased due to the 18:2n-6 
and 20:4n-6 supplements, in which the effect was larger 
for the 18:2n-6 supplemented cells. The extra 18:2n-6 
was incorporated as such or after one elongation step into 
the PC species 34:2, 36:2, 36:3, and 36:4, which raised 
their percentages in the 18:2n-6 supplemented cells com-
pared with the other cells. When the cells were supple-
mented with 20:4n-6, the percentages of 36:4, 38:4, and 
38:5 (having 20:4n-6 as the only significant PUFA compo-
nent) elevated compared with the control values (from 6, 
12, and 9% to 10, 23, and 13%, respectively).  In addi-
tion, highly unsaturated species with 22:4n-6 emerged, 
and the species 42:8 (20:4n-6/22:4n-6 with 7%) was spe-
cific for the 20:4n-6-supplemented cells. As for PC, the 
PE species 36:2, 36:3, and 36:4 (having 18:2n-6 or 20:2n-6 
as their PUFA component) showed prominent percent-
ages after the 18:2n-6 supplement (Fig. 6A). When 20:4n-6 
was given to the cells, the percentages of the 22:4n-
6-containing molecular species 40:4 and 40:5 elevated 
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Different n-3 PUFA supplements incorporate into 
different GPL molecular species
Supplementing the hBMSCs with the n-3 PUFAs, either 
18:3n-3, 20:5n-3, or 22:6n-3 induced very specific GPL 
species profiles, different from each other and from the 
profiles seen in the cells grown in standard or n-6 PUFA-
supplemented media (Figs. 5, 8). Among the most promi-
nent changes seen in the PC species profile with every n-3 
PUFA supplementation were the relative decreases (by 
more  than  40%)  of  the  SFA/MUFA  species  (32:1,  34:1, 
36:1) and the species 34:2 and 36:2 (Fig. 8). The cells sup-
plemented with 18:3n-3 showed the lowest percentages for 
these species containing mainly MUFAs. These relative re-
ductions in MUFA-containing species were accompanied 
by elevations in the proportions of polyunsaturated spe-
cies. For instance the 18:3n-3 supplement raised the per-
centage  of  34:3  (16:0/18:3n-3)  from  the  1%  level  of  the 
control cells to 12%. In addition, the percentages of 36:3, 
36:4 (the main molecular species being 18:0/18:3n-3 and 
18:1/18:3n-3, respectively), and 38:6 (including 18:3n-
3/20:3n-3) were more than doubled compared with the 
control cells grown in the medium supplemented only with 
FBS. Compared with the control cells, the 20:5n-3 supple-
ment caused manifold relative increases in the species 
36:5 (16:0/20:5n-3), 38:5 (mainly 18:0/20:5n-3), 40:5 
(18:0/22:5n-3), 38:6 (16:0/22:6n-3 and 16:1/22:5n-3), and 
40:6 (18:1/22:5n-3 and 18:0/22:6n-3). Concomitantly, the 
20:4n-6-containing species, 36:4 and 38:4, decreased to 
1.5%, lower than with any other supplements. With extra 
20:5n-3, a long-chain and highly unsaturated 42:10 emerged 
with  almost  3%.  Like  the  20:5n-3  supplement,  added 
22:6n-3 also boosted 22:6n-3-containing PC species 38:6 
and 40:6, which reached about 10% levels. In addition, the 
3-fold reaching 10% and 23% levels, respectively. In ad-
dition,  PE  species  with  two  PUFAs  (42:7,  42:8,  42:9) 
emerged after both n-6 PUFA supplements. Among PEp 
species, the 36:4p and 38:4p served as the largest reser-
voirs of 20:4n-6, and only a slight increase of the 22:4n-6 
containing 40:4p was found in the 20:4n-6-supplemented 
cells (Fig. 6B). The 20:4n-6 supplement reduced the per-
centages  of  22:6n-3-containing  PEp  species  38:6p,  40:6p 
and 40:7p.
Contrasting the diverse PC and PE species profiles, the 
hBMSC PSs consisted of only a few main species (Fig. 7). 
Both n-6 PUFA supplements halved the relative amounts 
of the monounsaturated PS species 36:1 (18:0/18:1), 
which was present with a roughly 50% level in the control 
cells and with 25‒30% in the supplemented cells (Fig. 7). 
When the cells received extra 18:2n-6, the species 36:2 
(18:0/18:2n-6) became the dominant PS species of the 
cells  with  60%.  When  20:4n-6  was  added,  the  propor-
tion of 38:4 (18:0/20:4n-6) doubled compared with the 
control values (from 5% to 11%). The largest PS indica-
tor species of the 20:4n-6 supplementation was 40:4 
(18:0/22:4n-6), the percentages of which elevated 5-fold, 
from 8% in the control cells to 42% in the supplemented 
cells. The main 22:6n-3-containing PS species, 40:6, de-
creased  from 7%  to below 1%  in  the n-6 PUFA-supple-
mented cells. In hBMSC PIs, only two quantitatively 
important species were found. The main molecular spe-
cies was 38:4 (18:0/20:4n-6), the percentages of which 
remained unaltered in the n-6 PUFA supplementations. 
However, the percentages of a minor component, 38:5 
(18:1/20:4n-6), increased (at the expense of several trace 
components not shown) due to the 20:4n-6 supplement 
(Fig. 7 insert).
Fig. 5. PC species profiles in hBMSCs cultured for 9 
days in the control (Ctrl) medium or medium supple-
mented with 18:2n-6 or 20:4n-6 (mole percent per to-
tal PC, mean ± SD). For the isobaric species (marked 
horizontally) having more than one quantitatively im-
portant species (acyl chain combination marked verti-
cally), the two most important are listed (in the 
reading order, the first one being the main species). 
When the double bond positions of the acyl chains 
were not marked, several isomers (revealed by GC-MS 
of fatty acids) were present in the cells for that particu-
lar chain. Statistics are as in Fig. 1.
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Fig. 6.  PE (A) and PEp (B) species profiles in hBMSCs cultured for 9 days in the control (Ctrl) medium or 
medium supplemented with 18:2n-6 or 20:4n-6 (mole percent per total PE or PEp, mean ± SD). For the iso-
baric species (marked horizontally) having more than one quantitatively important species (acyl and alkenyl 
chain combination marked vertically), the two most important are listed (in the reading order, the first one 
being the main species). When the double bond positions of the acyl chains were not marked, several isomers 
(revealed by GC-MS of fatty acids) were present in the cells for that particular chain. Statistics are as in Fig. 1.
proportion of 40:7 (18:1/22:6n-3) elevated to 9% with the 
22:6n-3 supplement, higher than with any other fatty acid 
supplementation.
In PE profiles of hBMSCs,  the  species 34:1, 34:2, 36:1, 
and 36:2 (18:1/18:1) decreased due to all types of n-3 
PUFA supplements. The n-3 PUFAs paired with SFAs and 
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boosted species were 38:6p (3-fold), 40:6p (1.5-fold), and 
40:7p (2-fold).
The PS species profiles of the hBMSCs supplemented 
with 18:3n-3 showed a specific appearance of 36:3 with a 
7% level (Fig. 10). Surprisingly, 18:3n-3 was not able to sig-
nificantly modify the percentages of the other five quanti-
tatively important polyunsaturated species 38:3, 38:4, 40:4, 
40:5, or 40:6. In contrast, the 20:5n-3 and 22:6n-3 supple-
ments decreased the percentages of 38:3, 38:4, and 40:4 
to one-half or more of the values found for the control 
and 18:3n-3-supplemented cells. Compared with the cells 
grown in control medium, the 20:5n-3 supplement raised 
the percentage of 40:5 (18:0/22:5n-3) 3-fold (to 52%), and 
the 22:6n-3 supplement raised the share of 40:6 (18:0/22:6n-
3) 6-fold (to 45%). The PI species profiles of the hBMSCs 
were altered little due to the 18:3n-3 supplement (Fig. 10 
insert). In contrast, exogenous 20:5n-3 and 22:6n-3 re-
placed part of 20:4n-6 in the main PI species, 38:4 (18:0/ 
20:4n-6), thus causing manifold increases in the propor-
tions of minor components with 20:5n-3 (38:5) or 22:6n-3 
(40:6 and 40:7).
Specific and large alterations in 20:4n-6, 20:5n-3, and 
22:6n-3 distribution patterns between the GPL classes of 
hBMSCs supplemented with different PUFAs
Compared with the control hBMSCs, the 18:2n-6 supple-
mentation did not elevate the 20:4n-6 content in the GPLs 
competed out MUFAs and 18:2n-6 (Fig. 9A). The added 
18:3n-3 even raised the percentage of 36:4 (18:1/18:3n-3 as 
the main component) 10-fold (to 12%) and elevated per-
centages were also found for 36:3 and 36:5. Unlike the 
other n-3 PUFA supplements, added 18:3n-3 kept the iso-
baric species 38:4 high, which was due to the elevated 
percentage of the molecular species 18:1/20:3n-3. With 
the 20:5n-3 and 22:6n-3 supplements, the proportions of 
n-6 PUFA-containing PE species 38:4 (18:0/20:4n-6 and 
16:0/22:4n-6)  decreased  to  5%,  one-third  of  the  values 
found in the cells cultured with standard medium. Addi-
tion  of  20:5n-3  raised  the  proportions  of  PE  38:6  (in 
these cells largely 18:1/20:5n-3) and 40:5 (18:0/22:5n-3) 
close  to 15%, 2-fold  those  in  the other hBMSCs. When 
the hBMSCs were supplemented with 22:6n-3, the per-
centage of PE 40:7 (18:1/22:6n-3) elevated 5-fold to 32%, 
and the species 40:8 (in these cells largely 18:2n-
6/22:6n-3) elevated 3-fold to 12%. Both the 22:5n-3 and 
22:6n-3  supplements  raised  the  percentage  of  PE  40:6 
(18:1/22:5n-3 and 18:0/22:6n-3 as the main species, re-
spectively). In PEp, the supplements 20:5n-3 and 22:6n-3 
decreased the percentages of the 20:4n-6- and 22:4n-
6-containing species 36:4p and 38:4p to one-half of the 
control values (Fig. 9B). In contrast, supplementing the 
cells with 18:3n-3 had no such effect. After the cells re-
ceived extra 20:5n-3, the species 36:5p and 38:5p showed 
elevated percentages, and when 22:6n-3 was given, the 
Fig. 7. PS species profiles in hBMSCs cultured for 9 
days in the control (Ctrl) medium or medium supple-
mented with 18:2n-6 or 20:4n-6 (mole percent per to-
tal PS, mean ± SD). For the isobaric species (marked 
horizontally) having more than one quantitatively im-
portant species (acyl chain combination marked verti-
cally), the two most important were listed (in the 
reading order the first one being the main species). 
Quantitatively important PI species are shown in the 
insert. When the double bond positions of the acyl 
chains were not marked, several isomers (revealed by 
GC-MS of fatty acids) were present in the cells for that 
particular chain. Statistics are as in Fig. 1.
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lesser degree than when using these highly unsaturated 
fatty acids themselves as the supplement (Fig. 11B, C).
Contrasting the effects of the 18:3n-3 supplement, pro-
viding the cells with the long and highly unsaturated 
20:5n-3 and 22:6n-3 efficiently replaced 20:4n-6 in PC, PE, 
and PS species, and also caused mild, but statistically sig-
nificant, relative reductions of 20:4n-6 in PI (Fig. 11A). 
When the cells were supplemented with 20:5n-3, the 
20:4n-6 content of PC, 25% in the control cells, reduced to 
8%. In PE, the concomitant loss of 20:4n-6 due to the exog-
enous 20:5n-3 was  even more pronounced,  from 33%  to 





these highly unsaturated n-3 PUFAs decreased the 20:4n-6 
content from the 5% of the control cells to below 1%.
The 20:5n-3 supplement resulted in large roughly 15–
20% reserves of 20:5n-3 in all studied GPL classes, except 
PS (Fig. 11B). Even in PI, with a strict preference for 20:4n-
6, the 20:5n-3 replaced 20:4n-6 and, as the result, one-
fourth of the PI species served as potential donors of 
of  the  cells,  but  decreased  it  by  one-third  in  PC  and  PE 
(Fig. 11A).  When  given  18:2n-6,  the  PEp  class  kept  its 
20:4n-6 content unchanged. Despite the general contents 
of 20:4n-6 being characteristically low in PS, the percent 
decrease of 20:4n-6 content due to 18:2n-6 was the largest 
in PS. In contrast, the 20:4n-6 supplement doubled the 
20:4n-6 content in PC (from 25% to 53%) and PS (from 
5%  to  11%),  and  also  caused  a  significant  increment  of 
20:4n-6 in PE and PEp (from 30–33% to 40–41%). Most of 
the PI molecules of n-6 PUFA-supplemented cells con-
tained a 20:4n-6 residue. The n-6 PUFA supplements did 
not allow 20:5n-3 to be incorporated into any of the studied 
GPLs in any significant amount (Fig. 11B) and, in general, 
the n-6 PUFA supplements significantly decreased the 
22:6n-3 contents of GPLs (Fig. 11C).
The 18:3n-3 supplement failed to replace 20:4n-6 among 
the PC and PS species of the hBMSCs, and compared with 
the control cells, small but statistically significant relative 
decreases of 20:4n-6 content were seen in PE (by 24%) and 
PI (by 8%) (Fig. 11A). The precursor 18:3n-3 was incorpo-
rated into the PC species as such or as its immediate elon-
gation product, 20:3n-3 (Fig. 8), and thus this supplement 
affected the contents of 20:5n-3 and 22:6n-3 in PC to a 
Fig. 8. PC species profiles in hBMSCs cultured for 9 days in the control (Ctrl) medium or medium supple-
mented with 18:3n-3, 20:5n-3, or 22:6n-3 (mole percent per total PC, mean ± SD). For the isobaric species 
(marked horizontally) having more than one quantitatively important species (acyl chain combination 
marked vertically) the two most important are listed (in the reading order, the first one being the main spe-
cies). When the double bond positions of the acyl chains were not marked, several isomers (revealed by GC-
MS of fatty acids) were present in the cells for that particular chain. Statistics as in Fig. 1.
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when the long and highly unsaturated n-3 PUFA supple-
ments  efficiently  displaced  20:4n-6  in  PE  and  PS,  conse-
quently, the PI, PEp, and PC became even more important 
remaining sources of 20:4n-6 in these cells (Fig. 11A).
20:5n-3.  With  the  22:6n-3  supplement,  PE  contained  the 





isobaric species (marked horizontally) having more than one quantitatively important species (acyl and alkenyl 
chain combination marked vertically), the two most important are listed (in the reading order, the first one 
being the main species). When the double bond positions of the acyl chains were not marked, several isomers 
(revealed by GC-MS of fatty acids) were present in the cells for that particular chain. Statistics are as in Fig. 1.
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interact under the control of various neuronal, hormonal, 
and other chemical stimuli, including lipid mediators such 
as PGE2 derived from 20:4n-6 (42–44). Human bone mar-
row typically contains 50% levels of MUFAs, 30% SFAs, and 
20%  PUFAs  (45).  When  hBMSCs  are  isolated  from  the 
marrow and expanded in culture, where the lipid and fatty 
acid supplements originate from bovine serum, their nour-
ishment and activation conditions may change. Recently, 
physiologically relevant levels of SFAs were found to reduce 
hBMSC proliferation and viability, the effects of which 
were prevented by the major MUFA, 18:1n-9 (46). In addi-
tion, in adipocytes and circulating immune cells, SFAs have 
been found to activate Toll-like receptor 4 (TLR4), conse-
quently initiating inflammatory cascades and recruiting 
proinflammatory M1 macrophages (47). Apparently stro-
mal cells and other cell types of the marrow require the 
high MUFA/SFA ratio, 1.5 in the marrow samples of this 
PGE2 production in hBMSCs supplemented with 20:4n-6, 
20:5n-3, or 22:6n-3
The hBMSCs initially grown in the control medium 
(with  5%  FBS)  or  in  the  medium  further  supplemented 
with either 20:4n-6, 20:5n-3, or 22:6n-3 were studied for the 
PGE2  concentration  they  secreted  into  serum-free  me-
dium. The cells supplemented with 20:4n-6 released PGE2 
concentrations 16-fold those released from the control 




Bone marrow niche is a complex lipid-rich tissue where 
different types of stem, progenitor, and differentiated cells 
Fig. 10. PS species profiles in hBMSCs cultured for 9 days in the control (Ctrl) medium or medium supple-
mented with 18:3n-3, 20:5n-3, or 22:6n-3 (mole percent per total PS, mean ± SD). For the isobaric species 
(marked horizontally) having more than one quantitatively important species (acyl chain combination 
marked vertically), the two most important are listed (in the reading order, the first one being the main spe-
cies). Quantitatively important PI species are shown in the insert. When the double bond positions of the acyl 
chains were not marked, several isomers (revealed by GC-MS of fatty acids) were present in the cells for that 
particular chain. Statistics are as in Fig. 1.
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was enriched in the cells almost 2-fold compared with me-
dium FBS. Thus the common culture medium provides the 
hBMSCs with few MUFAs and excessively bioactive PUFA 
precursors, especially 20:4n-6. In these conditions, the cells 
may have attenuated their COX signaling by actively elon-
gating the excess C20 PUFAs to C22 PUFAs. Notwithstand-
ing, the data suggest that FBS with its high 20:4n-6 content, 
especially, is not an optimal source of fatty acids for cul-
tured hBMSCs.
The SCD (9 desaturase) expression level of MSCs is 
high (41), and thus the low MUFA contents of the cultured 
hBMSCs were not due to their inability to synthesize them, 
but likely that their MUFA production was downregulated 
by their high PUFA contents, which is regarded as a mecha-
nism to maintain proper lipid viscosity. PUFAs have been 
proposed to bind to DNA regulatory areas and inhibit the 
production of the 9 desaturase enzyme responsible for 
the conversion of SFAs to MUFAs (53). Thus the additional 
work, for optimal functions. However, the MUFA/SFA ra-
tio of FBS and the hBMSCs grown with FBS was only 0.7. 
The current work showed that compared with the bone 
marrow,  FBS  was  especially  rich  in  the  PGE2  precursor, 
20:4n-6 (enriched 12-fold compared with marrow), but 
also contained larger relative amounts of 20:5n-3 (5-fold), 
22:5n-3 (7-fold), and 22:6n-3 (8-fold) than the marrow. 
The enzymes COX, LOX, and P450 have different speci-
ficities toward these different PUFA substrates, and the me-
diators formed have different functions and activities (48, 
49). Because the hBMSC level of 22:4n-6 was almost 4-fold 
compared with the FBS level, the cells apparently had elon-
gated part of the received bioactive 20:4n-6 to 22:4n-6. Due 
to its inhibitory effects on COX-1 and COX-2 activities, 
22:4n-6 is regarded as biologically less active than 20:4n-6 
(50, 51). In n-3 PUFAs, a similar, but less extensive, elonga-
tion of 20:5n-3 was seen, and consequently 22:5n-3, a more 
potent COX-1 and COX-2 inhibitor than 20:5n-3 (51, 52), 
Fig. 11. Distribution of lipid species carrying impor-
tant PUFA precursors of signaling molecules between 
different GPL classes in hBMSCs cultured for 9 days in 
the control (Ctrl) medium or medium supplemented 
with 18:2n-6, 20:4n-6, 18:3n-3, 20:5n-3, or 22:6n-3 
(mole percent sums of all species with the specific 
PUFA in each GPL class, mean ± SD). A: Distribution 
of species carrying 20:4n-6 between the GPL classes. B: 
Distribution of species carrying 20:5n-3 between the 
GPL classes. C: Distribution of species carrying 22:6n-3 
between the GPL classes. Statistics are as in Fig. 1.
 at T
erkko - N














Supplemental Material can be found at:
PUFA metabolism in mesenchymal stromal cells 107
amplifying and spreading the signal. Once 20:4n-6 or other 
PUFAs have been released from membrane GPLs, the ex-
cess of free PUFAs not transferred to lysoPC for re-acyla-
tion is converted to bioactive compounds by the COX, 
LOX, P450, and other pathways (61, 62). We measured 
relevant mRNA levels in the studied hBMSCs for the cru-
cial phospholipases, PLC, PLD, cPLA2IV, and sPLA2 (sup-
plemental Table S1), and also for COX-1 (PTGS1, 7.2), 
COX-2 (PTGS2, 7.1), several forms of LOX (e.g., ALOX12, 
6.2; ALOX15, 6.3; ALOX5, 6.1) and numerous members of 
the CYP (P450) family, which suggests that the hBMSCs 
had the capacity to generate a wide array of lipid mediators.
The substrate pools easily accessible for the lipid media-
tor generating enzymes are determined by various factors. 
For example the structures of the polar head group, the 
acyl chains, and their assemblies in the GPL species affect 
the efficiency of cleaving the sn-2 PUFA by phospholipases. 
The cPLA2IV preferentially liberates 20:4n-6 from the sn-2 
position and favors PC and PI as substrates, but also ac-
cepts PE with lower rates of hydrolysis (63). In human eo-
sinophilic leukemia cells, the activity of cPLA2 toward PE 
species with 20:5n-3 and 22:6n-3 was found to be much 
lower than toward the 20:4n-6-containing PE (64). Other 
PLA2 forms have different GPL class preferences and also 
use  PE  and  PEp  species  as  the  PUFA  donor  (65).  The 
phospholipase substrate preferences partly arise from the 
placement of the PUFA precursors in different molecular 
species of membrane GPLs. In addition to the reported 
preferences to hydrolyze a specific sn-2 acyl chain (e.g., 
20:4n-6 by cPLA2IV), the sn-1 acyl chain also affects the 
rate of GPL species hydrolysis due to the different degree 
of hydrophilicities and efflux propensities of different 
GPL species from the membrane bilayer (66–68). Func-
tional consequences follow since Dong et al. (51) found 
that the coadministered nonessential fatty acids, 16:0, 
18:1n-9, and 18:0 stimulated 20:4n-6-derived COX-2 activ-
ity, and the highest stimulation was recorded with the 
combination 16:0/20:4n-6, which species was kept as a mi-
nor component of the PC and PE of hBMSCs. The more 
prominent species of the hBMSCs, 18:0/20:4n-6, resulted 
in the experiment of Dong and coworkers in the lowest 
level of COX-2 stimulation. Thus the precise control of 
GPL species composition is likely crucial for the regula-
tion of cellular functions, such as inflammation, prolifera-
tion, and apoptosis.
The emergence of diPUFA species, e.g., PC42:8 and 
PE42:8  and  PE42:9  in  the  hBMSCs  supplemented  with 
20:4n-6 (50 M), suggests that after the primary low-capac-
ity and high-affinity pathway for PUFA incorporation into 
GPLs was saturated, the cells were forced to employ the 
high-capacity and low-affinity de novo pathway known to 
produce diPUFA species (62). The rates of hydrolysis of 
these different diPUFA species for possible lipid mediator 
production are not the same. A recent study indicated that 
cPLA2IV hydrolyzes PC molecular species 20:4n-6/20:4n-6 
with a rate superior to 22:6n-3/22:6n-3 and other PC spe-
cies (68). Exogenous 20:4n-6 increased the percentages of 
the polyunsaturated C42 species of the hBMSCs containing 
20:4n-6 coupled with 22:4n-6 or 22:5 (n-6 or n-3), which 
PUFA supplements, when further increasing the PUFA 
contents of the hBMSCs, reduced the contents of MUFAs 
even more. In addition, we found that the ability of the 
hBMSCs for structural modifications of the C18 PUFA pre-
cursors was limited compared with the frequently studied 
HepG2 cells. In HepG2 cells, exogenous 18:2n-6 or 18:3n-3 
were largely converted to their highly unsaturated prod-
ucts, while in hBMSCs these supplements raised the con-
tents of their own and those of their immediate chain 
elongation products, but were inefficient in raising the lev-
els of the most bioactive highly unsaturated PUFAs. The 
fatty acid profiles and the supporting enzyme data suggest 
that the desaturation steps, especially the 5 desaturation 
(FADS1) were inefficient in the hBMSCs.
On the metabolic pathway of PUFAs, the n-3 and n-6 
PUFAs are known to compete for the same elongation and 
desaturation enzymes, and thus the n-3 PUFA supplements 
were expected to inhibit the metabolic modifications of 
the n-6 PUFAs (54–57). In hBMSCs, the ability of different 
n-3 PUFA supplements to inhibit the metabolism of n-6 
PUFAs was very different. Supplementing the cells with the 
precursor, 18:3n-3, did not reduce their 20:4n-6 content as 
efficiently as 20:5n-3 or 22:6n-3 did. In fact, the18:3n-3 re-
duced the 22:5n-3 and 22:6n-3 contents of the hBMSCs, an 
effect not seen in the PUFA profiles of the HepG2 cells 
given the same supplement. Thus the manipulations 
intended to reduce hBMSC 20:4n-6 levels to favor anti- 
inflammatory instead of inflammatory signaling seem suc-
cessful only with the readymade long-chain and highly 
unsaturated n-3 PUFA supplements. Currently, these PUFAs 
are not added in sufficient amounts in the standard cell 
culture media. Because the 18:2n-6 supplement also re-
duced the hBMSC levels of 20:4n-6, the biosynthetic path-
ways toward the long and highly unsaturated fatty acids 
have likely been saturated due to the excess C18 PUFA 
precursor (58).
The PUFA-supplemented hBMSCs partly overcame the 
potential harmful effects of the excess PUFAs by incorpo-
rating them into TAGs. Interestingly, the accumulation of 
highly unsaturated TAGs was more pronounced in the 
hBMSCs cultured with n-6 PUFA supplements than in the 
cells cultured with the same concentration of n-3 PUFAs. 
This may mean that producing phospholipid membranes 
with high n-6 PUFA contents would have been more detri-
mental to the cellular functions than producing mem-
branes with high n-3 PUFA contents. In addition to finding 
part of the supplemented PUFAs deposited in storage 
TAGs, part of the PUFAs were incorporated into mem-
brane GPLs.
Manipulating the profiles of polyunsaturated GPLs by 
the PUFA supplements subsequently affects the precursor 
pool to be used for lipid mediator production. The factors 
controlling PUFA availability for hydrolysis from mem-
brane GPL and their transformation into different bioac-
tive lipid mediators are not yet fully elucidated. However, it 
is widely accepted that the cytosolic phospholipase A2 type 
IV (cPLA2IV) is responsible for the main part of the stimu-
lus-dependent mobilization of 20:4n-6 (59, 60). Secretory 
Ca2+-dependent PLA2 (sPLA2) and other lipases aid by 
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the inflammation status of the cells via eicosanoid or doco-
sanoid signaling.
Besides being a precursor for docosanoids with anti-in-
flammatory properties (75), 22:6n-3 influences membrane 
structure and protein function by affecting membrane 
packing, permeability, and lateral domain structure crucial 
for optimal functions of various integral proteins (76). In 
addition, 22:6n-3 can directly bind to receptors. For exam-
ple, 22:6n-3 is a ligand for macrophage GPR120 receptor 
initiating a signaling pathway through -arrestin2, which 
then inhibits TLR4 and inflammatory cytokine receptors, 
and reduces the inflammatory state of cells (77). Thus, ma-
nipulating the GPL contents of 22:6n-3 may have beneficial 
effects on the immunomodulatory properties of the cells 
via different mechanisms. In addition, 22:6n-3 was the only 
supplement that significantly increased its relative amount 
in PS. All other supplements decreased PS 22:6n-3 content. 
The 22:6n-3 affects Ca-dependent and -independent pro-
tein kinase C (PKC)-mediated signaling cascades. In mono-
cytic leukemia U937 cells, 22:6n-3 activated PLC, which 
released inositol-trisphosphate and calcium from endo-
plasmic reticulum-activating PKC. In a cell-free system, 
22:6n-3 activated PKC by binding directly to its PS-binding 
site, which activation was not found for 20:4n-6, 20:5n-3, or 
22:5n-3 (78). Thus, replacing 20:4n-6 by 22:6n-3 in the met-
abolically related PE and PS likely affects several signaling 
cascades via modulation of PKC activity in 22:6n-3-supple-
mented hBMSCs also. PC species containing 22:6n-3 were 
not found to promote PKC partitioning to membrane and 
activation (79).
The current results emphasize the importance of choos-
ing appropriate PUFA supplements for hBMSCs and other 
therapeutic cells cultured and expanded with artificial 
PUFA sources. Because the capacity of hBMSCs to modify 
PUFA structures is limited, the different supplements given 
result in very different GPL species profiles and substrate 
availability for phospholipases having preferences for polar 
head group and acyl chains. The chromatographic and 
mass spectrometric data obtained suggest that the hBMSCs 
are able to attenuate the possible harmful effect due to ex-
cess 20:4n-6 and subsequently enhanced PGE2 production 
by chain elongation of 20:4n-6 to 22:4n-6. Because supple-
mented 20:5n-3 and 22:6n-3 replaced 20:4n-6 in membrane 
GPLs, they apparently influenced eicosanoid/docosanoid 
signaling. In addition, the n-3 PUFA supplements modified 
membrane structure and thus modulated integral protein 
function, and as ligands, they likely participated in differ-
ent signaling pathways not yet elucidated for MSCs. This 
work lays foundations for understanding the functional 
consequences of different PUFA supplementations in 
hBMSCs, and the next question important to address in 
order to develop appropriate protocols for PUFA manipu-
lations of these therapeutic cells will be to study the kinetics 
of the acyl chain remodeling in different GPL classes. The 
ultimate goal is to characterize the changes of lipid media-
tor profiles caused by the PUFA supplements and carry out 
coculture experiments with hBMSCs and other cell types to 
monitor changes in biological functions and cellular inter-
actions.
may have had significantly lower hydrolysis rates and 
weaker signaling potential than the 20:4n-6/20:4n-6 spe-
cies. There is also other functional evidence that the elon-
gation of 20:4n-6 to 22:4n-6 and subsequent incorporation 
of 22:4n-6 into membrane GPLs may serve as a mechanism 
to attenuate inflammatory and apoptotic signaling due to 
excess 20:4n-6. COX activity experiments using 22:4n-6 as 
the substrate resulted in activities halved or smaller than 
those recorded with 20:4n-6 (50, 51). Having 22:4-6 as sub-
strate, COX-2 generates 1a,1b-dihomo PGE2, the biologi-
cal activity of which is regarded as much lower than the 
activity  of  PGE2  synthesized  from  20:4n-6.  As  far  as  we 
know, systematic studies addressing the functions and activ-
ity of the dihomo form do not exist. In line with these stud-
ies,  the  hBMSCs  with  high  20:4n-6  content  and  PGE2 
production also had  largely elevated  levels of PC and PE 
species 18:1/22:4n-6 (40:5), perhaps to hinder the boosted 
proinflammatory signaling.
Adjusting the levels of 20:4n-6 in cultured therapeutic 
cell lines is important for controlling their immunomodu-
latory properties. In our previous work, cultured hBMSCs 
expanded in several steps had lowered capacity to sup-
press the proliferation of T cells and increased GPL 
20:4n-6 content (13). Recently, Campos et al. (69) re-
ported that hBMSCs stimulated by proinflammatory cyto-
kines had enhanced levels of 20:4n-6-containing PC 
species 38:4. The 20:4n-6 signaling also has a pronounced 
role in tumor cells, which have high expression levels of 
PLA2s and COX-2, and enhanced production of PGE2 (70, 
71). Differentiation-related increase of GPL species with 
20:4n-6 was recently found in cultured neural stem cells 
(72). Using inhibitors for COX and PLA2 enzymes work-
ing on 20:4n-6 is one approach in the attempt to control 
cellular functions and fate in vivo. However, because these 
enzymes are part of essential pathways, and inhibitors for 
many PLA2 forms are unknown, an alternative holistic and 
relatively safe way to affect immune functions and viability 
of cells would be to manipulate the PUFA pool in the 
membranes of the therapeutic cells. As shown in this work, 
the  PGE2  production  of  hBMSCs  strongly  reflects  their 
supply and membrane contents of 20:4n-6, while the n-3 
PUFA supplements have only a small effect on the PGE2 
levels of the cells.
The 20:5n-3 or 22:6n-3 supplements lowering the 
20:4n-6 contents of PC limit the 20:4n-6-related eicosanoid 
signaling. Despite the preference of cPLA2IV to hydrolyze 
PUFAs from PC and PI, the transacylases further mediate 
the  newly  acquired  n-3  PUFAs  to  PEs  and  other  GPLs, 
which can then serve as n-3 PUFA donors for various li-
pases (73). Increasing the ratio of 20:5n-3/20:4n-6 in 
membrane GPLs is known to be manifested in an in-
creased ratio of the classic eicosanoids PGE3/PGE2, with 
well-known anti-inflammatory effects (51, 74). In addition, 
20:5n-3 and 22:6n-3 are precursors for resolvins, protec-
tins, and maresins, new generation mediators fortifying 
the resolution phase of inflammation (75). With 18:3n-3 
supplement, however, the GPL levels of 20:4n-6, 20:5n-3, 
or 22:6n-3 were affected relatively little. This suggests that 
18:3n-3, unlike 20:5n-3 (48, 49), has little potency to affect 
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